<DOC>
	<DOCNO>NCT01503112</DOCNO>
	<brief_summary>Type 2 diabetes major rapidly increase health problem worldwide . Keeping blood glucose ( sugar ) go high help prevent complication . Recently number new treatment ( collectively call 'incretin base ' treatment ) low blood glucose become available response variable difficult predict work individual . The investigator want see identify whether new treatment likely effective individual patient . Identifying right treatment would improve control minimise side-effects cost ineffective treatment . We collect blood ( measure blood glucose , insulin secretion genetics information ) , urine ( simple measurement insulin secretion ) clinical information ( weight , age , duration diabetes medication ) people start new 'incretin base ' treatment ass response first 6 month treatment . We analyse information see predict treatment response . Study Hypothesis : The investigator hypothesise low insulin secretion , measure post meal urine C-peptide Creatinine Ratio blood C-peptide , poor blood glucose response incretin base treatment .</brief_summary>
	<brief_title>Predicting Response Incretin Based Agents Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>A clinical diagnosis type 2 diabetes mellitus patient 's clinician determine need DPPIV inhibitor GLP1 analogue result inadequate glycaemic control HbA1c &gt; = 58mmol/mol Treatment DPPIV inhibitor GLP1 analogues prior study initiation ( within previous 3 month ) Renal failure show eGFR ( estimate glomerular filtration rate ) le 30 mL/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Glucagon-Like Peptide 1 , DPP4 protein , Therapeutics , Hypoglycemic Agents , C-Peptide , Type 2 Diabetes Mellitus ,</keyword>
</DOC>